Literature DB >> 27742173

Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa.

Alexander H Fischer1, Alessandra Haskin2, Ginette A Okoye3.   

Abstract

BACKGROUND: Antibiotic therapy is commonly used to treat hidradenitis suppurativa (HS). Although concern for antibiotic resistance exists, data examining the association between antibiotics and antimicrobial resistance in HS lesions are limited.
OBJECTIVE: We sought to determine the frequency of antimicrobial resistance in HS lesions from patients on antibiotic therapy.
METHODOLOGY: A cross-sectional analysis was conducted on 239 patients with HS seen at the Johns Hopkins Medical Institutions from 2010 through 2015.
RESULTS: Patients using topical clindamycin were more likely to grow clindamycin-resistant Staphylococcus aureus compared with patients using no antibiotics (63% vs 17%; P = .03). Patients taking ciprofloxacin were more likely to grow ciprofloxacin-resistant methicillin-resistant S aureus compared with patients using no antibiotics (100% vs 10%; P = .045). Patients taking trimethoprim/sulfamethoxazole were more likely to grow trimethoprim/sulfamethoxazole-resistant Proteus species compared with patients using no antibiotics (88% vs 0%; P < .001). No significant antimicrobial resistance was observed with tetracyclines or oral clindamycin. LIMITATIONS: Data on disease characteristics and antimicrobial susceptibilities for certain bacteria were limited.
CONCLUSIONS: Antibiotic therapy for HS treatment may be inducing antibiotic resistance. These findings highlight the importance of stewardship in antibiotic therapy for HS and raise questions regarding the balance of antibiotic use versus potential harms associated with antibiotic resistance.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acne inversa; antibiotics; antimicrobial resistance; hidradenitis suppurativa

Mesh:

Substances:

Year:  2016        PMID: 27742173     DOI: 10.1016/j.jaad.2016.08.001

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

Review 1.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments.

Authors:  Caroline Vinkel; Simon Francis Thomsen
Journal:  J Clin Aesthet Dermatol       Date:  2018-10-01

Review 2.  Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?

Authors:  Soha Ghanian; Mika Yamanaka-Takaichi; Haley B Naik; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2022-01-06       Impact factor: 6.233

3.  Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017.

Authors:  Eran Shavit; Afsaneh Alavi; Falk G Bechara; Richard G Bennett; Marc Bourcier; Ricardo Cibotti; Steven Daveluy; John W Frew; Amit Garg; Iltefat Hamzavi; Lauren K Hoffman; Jenny Hsaio; Joslyn Sciacca Kirby; Hadar Lev-Tov; Erin Martinez; Robert Micheletti; Haley B Naik; Aude Nassif; Cynthia Nicholson; Angie Parks-Miller; Zarine Patel; Vincent Piguet; Mayur Ramesh; Barry Resnik; Christopher Sayed; Gregory Schultz; Aamir Siddiqui; Jerry Tan; Ximena Wortsman; Michelle A Lowes
Journal:  Exp Dermatol       Date:  2019-01       Impact factor: 3.960

Review 4.  [Topical and novel device-based therapies for mild hidradenitis suppurativa].

Authors:  G Nikolakis; E von Stebut
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

Review 5.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

Review 6.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 7.  Hidradenitis suppurativa: an update on connecting the tracts.

Authors:  Mallory K Smith; Cynthia L Nicholson; Angela Parks-Miller; Iltefat H Hamzavi
Journal:  F1000Res       Date:  2017-07-28

8.  Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Authors:  G B E Jemec; M M Okun; S B Forman; W P F Gulliver; E P Prens; U Mrowietz; A W Armstrong; Z Geng; Y Gu; D A Williams; H D Teixeira; A B Kimball
Journal:  Br J Dermatol       Date:  2019-08-14       Impact factor: 9.302

9.  Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.

Authors:  Elisa Molinelli; Valerio Brisigotti; Oriana Simonetti; Claudia Sapigni; Giovanni Marco D'Agostino; Giulio Rizzetto; Alfredo Giacchetti; Annamaria Offidani
Journal:  Dermatol Ther       Date:  2022-03-18       Impact factor: 3.858

Review 10.  Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm.

Authors:  S Morteza Seyed Jafari; Robert E Hunger; Christoph Schlapbach
Journal:  Front Med (Lausanne)       Date:  2020-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.